Floatz logo

Therapeutic Asset Ratings

6,371 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
AssetSponsorPhaseRating
Nivolumab
Hodgkin'S Lymphoma, Lymphocytic-Histiocytic Predominance
National Cancer Institute (NCI)P3BB (64)
Nivolumab
Metastatic Cancer
Fred Hutchinson Cancer CenterP3BB (64)
Nivolumab
Metastatic Malignant Neoplasm
Fred Hutchinson Cancer CenterP3BB (64)
Nivolumab
Anal Canal Squamous Cell Carcinoma
National Cancer Institute (NCI)P3BB (64)
Nivolumab
Urothelial Carcinoma
Fred Hutchinson Cancer CenterP3BB (64)
Obinutuzumab
Diffuse Large B-Cell Lymphoma
National Cancer Institute (NCI)P3BB (64)
Obinutuzumab
Marginal Zone Lymphoma
Ruijin HospitalP3BB (64)
PANITUMUMAB
Malignant Pancreatic Neoplasm
SWOG Cancer Research NetworkP3BB (64)
Pembrolizumab
Colorectal Carcinoma
Roswell Park Cancer InstituteP3BB (64)
Pembrolizumab
Colorectal Neoplasm
GV20 TherapeuticsP3BB (64)
Pembrolizumab
Gastric Adenocarcinoma
EpkinP3BB (64)
Pembrolizumab
Gastric Cancer
Eikon TherapeuticsP3BB (64)
Pembrolizumab
Head And Neck Neoplasm
Mayo ClinicP3BB (64)
Pembrolizumab
Uterine Cervix Neoplasm
GV20 TherapeuticsP3BB (64)
Prolgolimab
Metastatic Melanoma
BiocadP3BB (64)
Solanezumab
Alzheimer Disease
Eli Lilly and CompanyP3BB (64)
Tiragolumab
Small Cell Lung Carcinoma
Hoffmann-La RocheP3BB (64)
Tislelizumab
Concurrent Chemoradiotherapy
Sun Yat-sen UniversityP3BB (64)
Tislelizumab
Diffuse Large B-cell Lymphoma
The First Affiliated Hospital with Nanjing Medical UniversityP3BB (64)
Tislelizumab
Metastatic Malignant Neoplasm
BeOne MedicinesP3BB (64)
Tislelizumab
Rectal Carcinoma
Fudan UniversityP3BB (64)
Tislelizumab
Rectal Neoplasm
Fudan UniversityP3BB (64)
Tislelizumab
Soft Tissue Sarcoma
Gustave Roussy, Cancer Campus, Grand ParisP3BB (64)
Toripalimab
Melanoma
West China HospitalP3BB (64)
Toripalimab
Small Cell Lung Carcinoma
Shanghai Best-Link Bioscience, LLCP3BB (64)
Showing 476 to 500 of 6,371 assets
PreviousPage 20 of 255Next